FDA Advisory Committee recommends approval of olodaterol* for maintenance treatment of COPD
29 January 2013 | By Boehringer Ingelheim
Olodaterol may provide a new treatment option in patients with COPD...
List view / Grid view
29 January 2013 | By Boehringer Ingelheim
Olodaterol may provide a new treatment option in patients with COPD...
17 January 2013 | By Boehringer Ingelheim
Submissions opened for diabetes research grant applications from across Europe...
17 January 2013 | By Boehringer Ingelheim
"Diabetes affects more than 371m people..."
16 January 2013 | By Boehringer Ingelheim
The acceptance of the NDA filing reinforces our ongoing commitment to oncology..."
7 January 2013 | By Boehringer Ingelheim
Top-line results for four completed Phase III clinical trials...
7 January 2013 | By Boehringer Ingelheim
Announces it will begin remainder of pre-planned clinical trials for LY2605541...
11 December 2012 | By Boehringer Ingelheim
Boehringer Ingelheim’s Metacam® has obtained EU wide marketing authorizations...
10 December 2012 | By Boehringer Ingelheim
Results from a new post-hoc analysis...
10 December 2012 | By Boehringer Ingelheim
New positive Phase II results...
5 December 2012 | By Boehringer Ingelheim
"We are very pleased to partner with Apexigen..."
14 November 2012 | By Boehringer Ingelheim
Today sees the culmination of weeklong activities at Boehringer Ingelheim...
13 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and BaroFold, Inc, have entered into a non-exclusive technology and commercial license option agreement...
12 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Molecular Partners have entered into a strategic manufacturing collaboration...
10 November 2012 | By Boehringer Ingelheim
Pivotal Phase III interferon-free study being initiated following positive Phase IIb results...
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...